Zacks, the Investment Research Firm, Reaffirmed BG Medicine's Rating

by Julia Samuel on May 4 2015 7:10 PM

Zacks, the Investment Research Firm, Reaffirmed BG Medicine
Zacks, the leading investment research firm restated BG Medicine (NASDAQ:BGMD)’s stock in a recent report.
Zacks’ analyst wrote, “BG Medicine, Inc. operates as a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers. The Company is focused on the development of blood-based tests and other candidates for cardiovascular and other diseases."

The report stated that it seeks partnerships with leading diagnostic laboratory instrument manufacturers for the development and commercialization of its products. The product candidates include products for Cardiovascular Disease, Central Nervous System (CNS) and Autoimmune Disorders. BG Medicine, Inc. is headquartered in Waltham, Massachusetts.

Shares of BG Medicine (NASDAQ:BGMD) traded up 8.7434% during mid-day trading and reached $0.7624. The stock had a trading volume of 131,041 shares. BG Medicine has a 52 week low of $0.2700 and a 52 week high of $1.3200. The stock’s 50-day moving average is $0.80 and its 200-day moving average is $0.62. The company’s market cap is $26.37 million.

BG Medicine reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. Analysts expect that BG Medicine will post $-0.1000 EPS for the current fiscal year.

BG Medicine, Inc (NASDAQ:BGMD) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics and focuses on blood-based tests.


Latest General Health News
View All